We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.59B
1-Year Est. Return 234.06%
This Fund
S&P 500
This Quarter Est. Return
+3.54%
1 Year Est. Return
+234.06%
3 Year Est. Return
+822.97%
5 Year Est. Return
+865.41%
10 Year Est. Return
+12,585.11%
AUM
$2.36B
AUM Growth
-$126M
Cap. Flow
+$59.8M
Cap. Flow %
2.53%
Top 10 Hldgs %
55.13%
Holding
55
New
9
Increased
3
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$85.6M
2
INZY
Inozyme Pharma
INZY
+$60.7M
3
ANNX icon
Annexon
ANNX
+$58.6M
4
MTCR
Metacrine, Inc. Common Stock
MTCR
+$31.4M
5
VRNA
Verona Pharma
VRNA
+$26.9M

Top Sells

Rank Stock Value
1
SPT icon
Sprout Social
SPT
+$109M
2
NET icon
Cloudflare
NET
+$49.6M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$44.4M
4
MRSN
Mersana Therapeutics
MRSN
+$40.4M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$5.93M

Sector Composition

Rank Sector Weight
1 Healthcare 87%
2 Technology 10.03%
3 Consumer Discretionary 1.95%
4 Industrials 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNCA
26
DELISTED
Genocea Biosciences, Inc.
GNCA
$23.8M 1.01%
10,376,936
+3,151,260
+44% +$8.27M
AVEO
27
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$23.5M 0.99%
3,952,958
– –
GERN icon
28
Geron
GERN
$835M
$23.4M 0.99%
+13,461,538
New +$24.9M
PHAS
29
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$23.3M 0.99%
6,643,704
– –
AFMD
30
DELISTED
Affimed
AFMD
$20.8M 0.88%
612,649
– –
CSBR icon
31
Champions Oncology
CSBR
$66.1M
$15.9M 0.67%
1,713,720
– –
CTIC
32
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$15.4M 0.65%
7,140,450
– –
IVA
33
Inventiva
IVA
$919M
$12.3M 0.52%
+1,041,666
New +$11.9M
LQDA icon
34
Liquidia Corp
LQDA
$5.88B
$12.2M 0.52%
2,486,062
– –
TRVN
35
DELISTED
Trevena, Inc.
TRVN
$11.4M 0.48%
6,099
– –
OBSV
36
DELISTED
ObsEva SA Ordinary Shares
OBSV
$11.4M 0.48%
4,586,563
– –
NET icon
37
Cloudflare
NET
$118B
$11.3M 0.48%
2,763,583
-1,295,793
-32% -$49.6M
XENE icon
38
Xenon Pharmaceuticals
XENE
$5.51B
$11M 0.47%
992,107
– –
DZSI
39
DELISTED
DZS Inc. Common Stock
DZSI
$8.96M 0.38%
956,255
– –
SBBP
40
DELISTED
Strongbridge Biopharma plc.
SBBP
$8.7M 0.37%
4,141,308
– –
SYBX
41
DELISTED
Synlogic
SYBX
$8.54M 0.36%
281,961
– –
MRKR icon
42
Marker Therapeutics
MRKR
$19.2M
$7.5M 0.32%
500,000
– –
LUMO
43
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$7.28M 0.31%
526,663
– –
SENS icon
44
Senseonics Holdings Inc
SENS
$473M
$5.52M 0.23%
707,660
-93,532
-12% -$829K
PHXM
45
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$3.75M 0.16%
62,500
– –
LXRX icon
46
Lexicon Pharmaceuticals
LXRX
$894M
$3.43M 0.15%
2,382,286
– –
TPST icon
47
Tempest Therapeutics
TPST
$17.5M
$2.88M 0.12%
9,060
– –
TCON
48
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$1.79M 0.08%
17,336
– –
DKNG icon
49
DraftKings
DKNG
$12B
$1.41M 0.06%
+23,902
New +$929K
RGLS
50
DELISTED
Regulus Therapeutics
RGLS
$1.05M 0.04%
205,246
– –
1
2
3

Similar funds

ADL
Asset Dedication LLC San Francisco, California $1.59B AUM 26.56% 1-Year Est. Return
CCP
Cryder Capital Partners London, United Kingdom $1.59B AUM 0.23% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
W
Wealthquest Cincinnati, Ohio $1.59B AUM 18.1% 1-Year Est. Return
PIS
PPSC Investment Service Tokyo, Japan $1.58B AUM 47.89% 1-Year Est. Return
FWP
Falcon Wealth Planning Ontario, California $1.58B AUM 20.99% 1-Year Est. Return

NEA Management Company's Q3 2020 Portfolio in Review

As of Q3 2020, NEA Management Company held 55 positions worth $2.36B, down 5.1% from $2.49B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

NEA Management Company's Q3 2020 filing shows 9 new, 3 increased, 6 reduced and 1 closed positions. Its largest new stake was Nkarta: 2,904,974 shares worth $87.3M. The largest sale was Sprout Social, an estimated $109M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 81% a quarter earlier, followed by Technology and Consumer Discretionary.

  • NEA Management Company's largest Q3 2020 buy was Nkarta: 2,904,974 shares worth $87.3M.
  • NEA Management Company added most to Verona Pharma in Q3 2020, an estimated $26.9M increase.
  • NEA Management Company's biggest Q3 2020 reduction was Sprout Social, cutting an estimated $109M.
  • NEA Management Company fully exited Rigel Pharmaceuticals in Q3 2020, selling an estimated $5.93M.
  • NEA Management Company's ten largest holdings make up 55% of its $2.36B portfolio in Q3 2020.
  • NEA Management Company opened 9 new positions and closed 1 in Q3 2020.
  • NEA Management Company's portfolio value fell 5.1% quarter-over-quarter to $2.36B.

Based on NEA Management Company's 13F filing for Q3 2020, filed 6 Nov 2020.